SkinBioTherapeutics (GB:SBTX) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
SkinBioTherapeutics has finalized a commercial agreement with Croda Beauty Care, marking a significant step towards launching its SkinBiotix technology in the cosmetics market. The company anticipates becoming cash flow positive by FY2025, driven by expected sales from the Croda deal and recent acquisitions such as Dermatonics and Bio-Tech Solutions. The launch of SkinBiotix as an active ingredient is set for April 2025 at the In-Cosmetics Global exhibition in Amsterdam.
For further insights into GB:SBTX stock, check out TipRanks’ Stock Analysis page.